Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Debt (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Total Debt for 6 consecutive years, with $4.6 million as the latest value for Q2 2017.

  • Quarterly Total Debt fell 79.49% to $4.6 million in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Jun 2017, down 79.49% year-over-year, with the annual reading at $14.7 million for FY2016, 46.66% down from the prior year.
  • Total Debt hit $4.6 million in Q2 2017 for Corcept Therapeutics, down from $10.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $35.1 million in Q1 2014 to a low of $4.6 million in Q2 2017.
  • Historically, Total Debt has averaged $27.3 million across 5 years, with a median of $32.1 million in 2015.
  • Biggest five-year swings in Total Debt: increased 13.3% in 2013 and later tumbled 79.49% in 2017.
  • Year by year, Total Debt stood at $35.1 million in 2013, then fell by 3.36% to $33.9 million in 2014, then fell by 18.87% to $27.5 million in 2015, then crashed by 46.66% to $14.7 million in 2016, then crashed by 68.81% to $4.6 million in 2017.
  • Business Quant data shows Total Debt for CORT at $4.6 million in Q2 2017, $10.1 million in Q1 2017, and $14.7 million in Q4 2016.